BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 2223417)

  • 1. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?
    Joubert PH; Venter HL; Foukaridis GN
    Br J Clin Pharmacol; 1990 Sep; 30(3):391-6. PubMed ID: 2223417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of miglitol and acarbose on starch digestion, daily plasma glucose profiles and cataract formation.
    Madar Z; Hazan A
    J Basic Clin Physiol Pharmacol; 1993; 4(1-2):69-81. PubMed ID: 8679512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase.
    Joubert PH; Foukaridis GN; Bopape ML
    Eur J Clin Pharmacol; 1987; 31(6):723-4. PubMed ID: 3549325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus.
    Reuser AJ; Wisselaar HA
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():19-24. PubMed ID: 8001622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of alpha-inhibitors on blood glucose and insulin levels.
    Laube H; Federlin K; Hillebrand I
    Adv Exp Med Biol; 1988; 246():287-93. PubMed ID: 3074658
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of alpha-glucosidase inhibitors on mouth to caecum transit time in humans.
    Ladas SD; Frydas A; Papadopoulos A; Raptis SA
    Gut; 1992 Sep; 33(9):1246-8. PubMed ID: 1427379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of acarbose and miglitol (BAY-M-1099) on postprandial glucose levels following ingestion of various sources of starch by nondiabetic and streptozotocin-induced diabetic rats.
    Madar Z
    J Nutr; 1989 Dec; 119(12):2023-9. PubMed ID: 2695605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
    Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
    Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.
    Sels JP; Nauta JJ; Menheere PP; Wolffenbuttel BH; Nieuwenhuijzen Kruseman AC
    Br J Clin Pharmacol; 1996 Oct; 42(4):503-6. PubMed ID: 8904624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Miglitol, a new alpha-glucosidase inhibitor.
    Sels JP; Huijberts MS; Wolffenbuttel BH
    Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
    Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
    Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibitors of alpha-glucosidase].
    Toeller M
    Journ Annu Diabetol Hotel Dieu; 1991; ():203-12. PubMed ID: 1886331
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of miglitol administration to non-insulin-dependent diabetic rats.
    Tormo MA; Ropero MF; Nieto M; Martinez IM; Campillo JE
    Gen Pharmacol; 1998 Jan; 30(1):125-9. PubMed ID: 9457493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
    Scott LJ; Spencer CM
    Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
    Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
    Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of alpha-glucosidase inhibition.
    Bischoff H
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():3-10. PubMed ID: 8001624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
    Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
    Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
    Axen KV; Li X; Sclafani A
    Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes.
    Tattersall R
    Diabet Med; 1993 Oct; 10(8):688-93. PubMed ID: 8261749
    [No Abstract]   [Full Text] [Related]  

  • 20. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
    Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
    J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.